Page last updated: 2024-11-05

pyrvinium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

pyrvinium: RN given refers to parent cpd; synonyms vanquin & vankin refer to pamoate[2:1]; structure in Merck Index, 9th ed, #7810 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pyrvinium : A quinolinium ion that is 1-methylquinolinium substituted by dimethylamino group at position 6 and a (E)-2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl at position 2. It is a anthelminthic drug active against pinworms. The salts of pyrvinium can also be used as anticancer agents. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5281035
CHEMBL ID1201303
CHEBI ID8687
MeSH IDM0083058

Synonyms (27)

Synonym
pyrvinium
C07412
7187-62-4
6-(dimethylamino)-2-(2-(2,5-dimethyl-1-phenyl-1h-pyrrol-3-yl)ethenyl)-1-methylquinolinium
quinolinium, 6-(dimethylamino)-2-(2-(2,5-dimethyl-1-phenyl-1h-pyrrol-3-yl)ethenyl)-1-methyl-
pyrvinum
hsdb 3178
quinolinium, 6-(dimethylamino)-2-(2-(2,5-dimethyl-1-phenylpyrrol-3-yl)vinyl)-1-methyl-
2-[(e)-2-(2,5-dimethyl-1-phenylpyrrol-3-yl)ethenyl]-n,n,1-trimethylquinolin-1-ium-6-amine
pyrvinium cation
CHEMBL1201303
pyrvinum (base)
pyrvinium (cation)
chebi:8687 ,
pyrvinium ion
6-(dimethylamino)-2-[(e)-2-(2,5-dimethyl-1-phenyl-1h-pyrrol-3-yl)ethenyl]-1-methylquinolinium
unii-6b9991flu3
6b9991flu3 ,
pyrvinium [hsdb]
6-(dimethylamino)-2-(2-(2,5-dimethyl-1-phenyl-1h-pyrrol-3-yl)vinyl)-1-methylquinolinium
DTXSID2043795
2-[(e)-2-(2,5-dimethyl-1-phenyl-pyrrol-3-yl)vinyl]-n,n,1-trimethyl-quinolin-1-ium-6-amine
AB00053809_02
DB06816
Q264039
pyrvinium-pamoate
bdbm50587736

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"An anthelminthic, pyrvinium pamoate (PP), 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-quinolinium pamoate salt, has been found to be extremely toxic to PANC-1 cells in glucose-free medium, but not to be toxic to the same cells cultured in ordinary medium, Dulbecco's modified Eagle's medium (DMEM)."( Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-quinolinium pamoate salt, showing preferential cytotoxicity during glucose starvation.
Esumi, H; Hanaoka, T; Kurashima, Y; Lu, J, 2004
)
0.32

Bioavailability

ExcerptReferenceRelevance
" Investigation and modification of the bioavailability and toxicity profile of systemic PP are warranted."( The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer.
Atkinson, RL; Debeb, BG; Hang, BI; Klopp, AH; Krishnamurthy, S; Lacerda, L; Lee, E; Li, L; McMurray, JS; Orton, D; Reuben, JM; Solley, TN; Ueno, NT; Woodward, WA; Xu, W, 2013
)
0.39
" However, its poor bioavailability limited the ability to test this first-in-class WNT inhibitor in vivo."( Differential abundance of CK1α provides selectivity for pharmacological CK1α activators to target WNT-dependent tumors.
Abreu, MT; Astudillo, L; Capobianco, AJ; Chen, X; Cobb, MH; Doundoulakis, T; Fei, DL; Guerra, ML; Jin, K; Kirkbride, KC; Lee, E; Li, B; Long, J; Marchetti, F; Neitzel, LR; Nguyen, DM; Orton, D; Robbins, DJ; Rodriguez-Blanco, J; Sands, LR; Shen, C; Thorne, C; Wang, Z; Zaias, J, 2017
)
0.46
" The pharmacokinetic and pharmacodynamic (PK/PD) profile of PP and bioavailability in humans will be used as the secondary objective."( Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma.
Bowne, WB; Brody, JR; Cannaday, S; Lavu, H; Leiby, BE; Nevler, A; Ponzini, FM; Posey, J; Schultz, CW; Yeo, C; Yeo, T, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" In addition, the medical grades and dosage forms of several brands of pyrvinium pamoate were examined for purity by fluorescence high pressure liquid chromatography (HPLC) using a methanol:water (90:10) solvent system."( The detection of chemical impurities by high pressure liquid chromatography and the genetic activity of medical grades of pyrvinium pamoate in Saccharomyces cerevisiae and Salmonella typhimurium.
Chatten, LG; Hennig, UG; Pon, RA; von Borstel, RC, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
anthelminthic drugSubstance intended to kill parasitic worms (helminths).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
quinolinium ion
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Regulation of Wnt / B-catenin signaling by small molecule compounds010

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Synaptojanin-2Homo sapiens (human)IC50 (µMol)1.25000.87404.137310.0000AID1620742; AID1621365; AID1634424
Synaptojanin-1Homo sapiens (human)IC50 (µMol)1.00001.00001.00001.0000AID1620743; AID1621366
Androgen receptorHomo sapiens (human)IC50 (µMol)0.19000.00000.875310.0000AID1885122
Serine hydroxymethyltransferase, mitochondrialHomo sapiens (human)IC50 (µMol)2.57040.43653.58839.7700AID1619186
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Casein kinase I isoform alphaHomo sapiens (human)Kd0.00100.00102.575619.3520AID1845988
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (98)

Processvia Protein(s)Taxonomy
phosphatidylinositol biosynthetic processSynaptojanin-2Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processSynaptojanin-2Homo sapiens (human)
synaptic vesicle endocytosisSynaptojanin-2Homo sapiens (human)
membrane organizationSynaptojanin-2Homo sapiens (human)
phosphatidylinositol dephosphorylationSynaptojanin-2Homo sapiens (human)
phosphatidylinositol biosynthetic processSynaptojanin-1Homo sapiens (human)
neurotransmitter transportSynaptojanin-1Homo sapiens (human)
learningSynaptojanin-1Homo sapiens (human)
synaptic vesicle primingSynaptojanin-1Homo sapiens (human)
synaptic vesicle uncoatingSynaptojanin-1Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processSynaptojanin-1Homo sapiens (human)
inositol phosphate metabolic processSynaptojanin-1Homo sapiens (human)
phosphatidylinositol metabolic processSynaptojanin-1Homo sapiens (human)
phosphatidylinositol dephosphorylationSynaptojanin-1Homo sapiens (human)
synaptic vesicle endocytosisSynaptojanin-1Homo sapiens (human)
synaptic vesicle transportSynaptojanin-1Homo sapiens (human)
membrane organizationSynaptojanin-1Homo sapiens (human)
positive regulation of endosome organizationSynaptojanin-1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
MAPK cascadeAndrogen receptorHomo sapiens (human)
in utero embryonic developmentAndrogen receptorHomo sapiens (human)
regulation of systemic arterial blood pressureAndrogen receptorHomo sapiens (human)
epithelial cell morphogenesisAndrogen receptorHomo sapiens (human)
transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
signal transductionAndrogen receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAndrogen receptorHomo sapiens (human)
cell-cell signalingAndrogen receptorHomo sapiens (human)
spermatogenesisAndrogen receptorHomo sapiens (human)
single fertilizationAndrogen receptorHomo sapiens (human)
positive regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
negative regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
positive regulation of gene expressionAndrogen receptorHomo sapiens (human)
male somatic sex determinationAndrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
intracellular receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
Leydig cell differentiationAndrogen receptorHomo sapiens (human)
multicellular organism growthAndrogen receptorHomo sapiens (human)
positive regulation of phosphorylationAndrogen receptorHomo sapiens (human)
positive regulation of MAPK cascadeAndrogen receptorHomo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of cell differentiationAndrogen receptorHomo sapiens (human)
negative regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIIAndrogen receptorHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
regulation of developmental growthAndrogen receptorHomo sapiens (human)
animal organ formationAndrogen receptorHomo sapiens (human)
male genitalia morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell proliferationAndrogen receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationAndrogen receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityAndrogen receptorHomo sapiens (human)
activation of prostate induction by androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
morphogenesis of an epithelial foldAndrogen receptorHomo sapiens (human)
lateral sprouting involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
prostate gland growthAndrogen receptorHomo sapiens (human)
prostate gland epithelium morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell differentiation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
mammary gland alveolus developmentAndrogen receptorHomo sapiens (human)
positive regulation of epithelial cell proliferation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
cellular response to steroid hormone stimulusAndrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusAndrogen receptorHomo sapiens (human)
cellular response to testosterone stimulusAndrogen receptorHomo sapiens (human)
seminiferous tubule developmentAndrogen receptorHomo sapiens (human)
non-membrane-bounded organelle assemblyAndrogen receptorHomo sapiens (human)
positive regulation of miRNA transcriptionAndrogen receptorHomo sapiens (human)
regulation of protein localization to plasma membraneAndrogen receptorHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayAndrogen receptorHomo sapiens (human)
male gonad developmentAndrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayAndrogen receptorHomo sapiens (human)
regulation of oxidative phosphorylationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
glycine metabolic processSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
L-serine metabolic processSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
L-serine biosynthetic processSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
one-carbon metabolic processSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
positive regulation of cell population proliferationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
response to type I interferonSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
tetrahydrofolate interconversionSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
tetrahydrofolate metabolic processSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
protein tetramerizationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
protein homotetramerizationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
regulation of mitochondrial translationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
protein K63-linked deubiquitinationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
regulation of aerobic respirationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
glycine biosynthetic process from serineSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
protein phosphorylationCasein kinase I isoform alphaHomo sapiens (human)
Golgi organizationCasein kinase I isoform alphaHomo sapiens (human)
cell surface receptor signaling pathwayCasein kinase I isoform alphaHomo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform alphaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform alphaHomo sapiens (human)
viral protein processingCasein kinase I isoform alphaHomo sapiens (human)
cellular response to nutrientCasein kinase I isoform alphaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase I isoform alphaHomo sapiens (human)
positive regulation of Rho protein signal transductionCasein kinase I isoform alphaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processCasein kinase I isoform alphaHomo sapiens (human)
intermediate filament cytoskeleton organizationCasein kinase I isoform alphaHomo sapiens (human)
cell divisionCasein kinase I isoform alphaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayCasein kinase I isoform alphaHomo sapiens (human)
negative regulation of NLRP3 inflammasome complex assemblyCasein kinase I isoform alphaHomo sapiens (human)
positive regulation of TORC1 signalingCasein kinase I isoform alphaHomo sapiens (human)
signal transductionCasein kinase I isoform alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (43)

Processvia Protein(s)Taxonomy
RNA bindingSynaptojanin-2Homo sapiens (human)
phosphatidylinositol-3-phosphate phosphatase activitySynaptojanin-2Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate 5-phosphatase activitySynaptojanin-2Homo sapiens (human)
protein bindingSynaptojanin-2Homo sapiens (human)
phosphatidylinositol phosphate 4-phosphatase activitySynaptojanin-2Homo sapiens (human)
phosphatidylinositol-3,5-bisphosphate 5-phosphatase activitySynaptojanin-2Homo sapiens (human)
phosphatidylinositol-3,5-bisphosphate 3-phosphatase activitySynaptojanin-2Homo sapiens (human)
SH3 domain bindingSynaptojanin-2Homo sapiens (human)
PDZ domain bindingSynaptojanin-2Homo sapiens (human)
RNA bindingSynaptojanin-1Homo sapiens (human)
phosphatidylinositol-3-phosphate phosphatase activitySynaptojanin-1Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate 5-phosphatase activitySynaptojanin-1Homo sapiens (human)
protein bindingSynaptojanin-1Homo sapiens (human)
phosphatidylinositol phosphate 5-phosphatase activitySynaptojanin-1Homo sapiens (human)
phosphatidylinositol phosphate 4-phosphatase activitySynaptojanin-1Homo sapiens (human)
phosphatidylinositol-4-phosphate phosphatase activitySynaptojanin-1Homo sapiens (human)
phosphatidylinositol-3,5-bisphosphate 5-phosphatase activitySynaptojanin-1Homo sapiens (human)
phosphatidylinositol-3,5-bisphosphate 3-phosphatase activitySynaptojanin-1Homo sapiens (human)
inositol-1,4,5-trisphosphate 5-phosphatase activitySynaptojanin-1Homo sapiens (human)
SH3 domain bindingSynaptojanin-1Homo sapiens (human)
transcription cis-regulatory region bindingAndrogen receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
RNA polymerase II general transcription initiation factor bindingAndrogen receptorHomo sapiens (human)
transcription coactivator bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
chromatin bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityAndrogen receptorHomo sapiens (human)
nuclear receptor activityAndrogen receptorHomo sapiens (human)
G protein-coupled receptor activityAndrogen receptorHomo sapiens (human)
signaling receptor bindingAndrogen receptorHomo sapiens (human)
steroid bindingAndrogen receptorHomo sapiens (human)
androgen bindingAndrogen receptorHomo sapiens (human)
protein bindingAndrogen receptorHomo sapiens (human)
beta-catenin bindingAndrogen receptorHomo sapiens (human)
zinc ion bindingAndrogen receptorHomo sapiens (human)
enzyme bindingAndrogen receptorHomo sapiens (human)
ATPase bindingAndrogen receptorHomo sapiens (human)
molecular adaptor activityAndrogen receptorHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingAndrogen receptorHomo sapiens (human)
POU domain bindingAndrogen receptorHomo sapiens (human)
molecular condensate scaffold activityAndrogen receptorHomo sapiens (human)
estrogen response element bindingAndrogen receptorHomo sapiens (human)
chromatin bindingSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
glycine hydroxymethyltransferase activitySerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
protein bindingSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
L-allo-threonine aldolase activitySerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
amino acid bindingSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
pyridoxal phosphate bindingSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
identical protein bindingSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
protein kinase activityCasein kinase I isoform alphaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform alphaHomo sapiens (human)
protein bindingCasein kinase I isoform alphaHomo sapiens (human)
ATP bindingCasein kinase I isoform alphaHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
cytosolSynaptojanin-2Homo sapiens (human)
cytoskeletonSynaptojanin-2Homo sapiens (human)
plasma membraneSynaptojanin-2Homo sapiens (human)
cell projectionSynaptojanin-2Homo sapiens (human)
membrane raftSynaptojanin-2Homo sapiens (human)
perinuclear region of cytoplasmSynaptojanin-2Homo sapiens (human)
presynapseSynaptojanin-2Homo sapiens (human)
microtubuleSynaptojanin-1Homo sapiens (human)
cytosolSynaptojanin-1Homo sapiens (human)
vesicle membraneSynaptojanin-1Homo sapiens (human)
terminal boutonSynaptojanin-1Homo sapiens (human)
perinuclear region of cytoplasmSynaptojanin-1Homo sapiens (human)
synaptic membraneSynaptojanin-1Homo sapiens (human)
presynapseSynaptojanin-1Homo sapiens (human)
membrane coatSynaptojanin-1Homo sapiens (human)
clathrin coat of coated pitSynaptojanin-1Homo sapiens (human)
perinuclear region of cytoplasmSynaptojanin-1Homo sapiens (human)
presynapseSynaptojanin-1Homo sapiens (human)
plasma membraneAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
nucleoplasmAndrogen receptorHomo sapiens (human)
cytoplasmAndrogen receptorHomo sapiens (human)
cytosolAndrogen receptorHomo sapiens (human)
nuclear speckAndrogen receptorHomo sapiens (human)
chromatinAndrogen receptorHomo sapiens (human)
protein-containing complexAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
nucleusSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
cytoplasmSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
mitochondrionSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
mitochondrial inner membraneSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
mitochondrial matrixSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
microtubule cytoskeletonSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
mitochondrial nucleoidSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
extracellular exosomeSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
BRISC complexSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
mitochondrionSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
cytoplasmSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
mRNA cleavage and polyadenylation specificity factor complexCasein kinase I isoform alphaHomo sapiens (human)
keratin filamentCasein kinase I isoform alphaHomo sapiens (human)
kinetochoreCasein kinase I isoform alphaHomo sapiens (human)
centrosomeCasein kinase I isoform alphaHomo sapiens (human)
spindleCasein kinase I isoform alphaHomo sapiens (human)
cytosolCasein kinase I isoform alphaHomo sapiens (human)
ciliumCasein kinase I isoform alphaHomo sapiens (human)
membraneCasein kinase I isoform alphaHomo sapiens (human)
nuclear speckCasein kinase I isoform alphaHomo sapiens (human)
beta-catenin destruction complexCasein kinase I isoform alphaHomo sapiens (human)
ciliary basal bodyCasein kinase I isoform alphaHomo sapiens (human)
cytoplasmCasein kinase I isoform alphaHomo sapiens (human)
nucleusCasein kinase I isoform alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID1617696Growth inhibition of human SW480 cells by Cell-titer-fluor reagent based assay2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/β-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation.
AID572363Antimicrobial activity against Cryptosporidium parvum infected in neonatal BALB/C mouse assessed as reduction in trophozoites in ileum at 5 mg/kg/day, po for 6 days by hematoxylin and eosin staining2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID649234Cytotoxicity against human HEK293T cells at 0.2 to 20 uM after 24 hrs by alamar blue assay2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Wnt inhibition correlates with human embryonic stem cell cardiomyogenesis: a structure-activity relationship study based on inhibitors for the Wnt response.
AID572165Antimicrobial activity against Cryptosporidium parvum infected in human HCT-8 cells after 48 hrs by ELISA2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID1617692Inhibition of Wnt/beta-Catenin signaling (unknown origin) expressed in recombinant human Wnt-3a-induced Wnt-HEK293 cells incubated for 24 hrs by luciferase reporter gene assay2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/β-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation.
AID572364Antimicrobial activity against Cryptosporidium parvum infected in neonatal BALB/C mouse assessed as reduction in trophozoites in appendix at 5 mg/kg/day, po for 6 days by hematoxylin and eosin staining2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID572361Antimicrobial activity against Cryptosporidium parvum infected in neonatal BALB/C mouse assessed as reduction in oocyst shedding at 5 mg/kg/day, po for 6 days treated 3 days postinfection2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID1845987Inhibition of Wnt/beta-catenin transactivation signalling in Wnt3a stimulated human HEK 293 STF cells harbouring TCF/LEF1 luciferase reporter gene assessed as reduction in luciferase activity by TOPFlash luciferase reporter assay2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID572166Cytotoxicity against human HCT8 cells assessed as reduction in viable cells after 48 hrs by MTS assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID649227Inhibition of beta-casein-dependent canonical Wnt3 pathway in human HEK293T cells by luciferase reporter gene assay2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Wnt inhibition correlates with human embryonic stem cell cardiomyogenesis: a structure-activity relationship study based on inhibitors for the Wnt response.
AID572377Antimicrobial activity against Cryptosporidium parvum infected in neonatal BALB/C mouse assessed as reduction in number of trophozoites at 5 mg/kg/day, po for 6 days2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID1845989Inhibition of hedgehog signalling in mouse Shh Light II cells assessed as luciferase activity2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID572167Cytotoxicity against human HCT8 cells assessed as reduction in viable cells after 48 hrs at 1.6 uM by MTS assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID572360Antimicrobial activity against Cryptosporidium parvum infected in neonatal BALB/C mouse assessed as reduction in oocyst shedding at 12.5 mg/kg/day, po for 4 days treated 3 days postinfection2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID572365Antimicrobial activity against Cryptosporidium parvum infected in neonatal BALB/C mouse assessed as reduction in trophozoites in colon at 5 mg/kg/day, po for 6 days by hematoxylin and eosin staining2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID1845988Binding affinity to CK1alpha (unknown origin) using casein as substrate by fluorescence based analysis2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID1575339Oral bioavailability in mouse2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Triazole-Based Inhibitors of the Wnt/β-Catenin Signaling Pathway Improve Glucose and Lipid Metabolisms in Diet-Induced Obese Mice.
AID1885122Antagonist activity at Androgen receptor in human LNCaP cells assessed as inhibition of DNA binding domain of AR measured by enhanced green fluorescent protein transcriptional (eGFPT) assay2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
Therapeutic Strategies to Target the Androgen Receptor.
AID572358Antimicrobial activity against Cryptosporidium parvum infected in neonatal BALB/C mouse assessed as reduction in oocyst shedding at 5 mg/kg/day, po for 4 days treated 3 days postinfection2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID1617697Inhibition of Wnt/beta-Catenin signaling (unknown origin) expressed in recombinant human Wnt-3a-induced Wnt-HEK293 cells assessed as increase in beta-catenin degradation at 1 uM by Western blot analysis2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/β-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation.
AID1575304Inhibition of Wnt3a activated Wnt/beta-catenin signaling (unknown origin) expressed in HEK293 cells harboring TCF/LEF-responsive luciferase preincubated with cells followed by Wnt3a addition and measured after 24 hrs by luciferase reporter gene assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Triazole-Based Inhibitors of the Wnt/β-Catenin Signaling Pathway Improve Glucose and Lipid Metabolisms in Diet-Induced Obese Mice.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (146)

TimeframeStudies, This Drug (%)All Drugs %
pre-199052 (35.62)18.7374
1990's3 (2.05)18.2507
2000's8 (5.48)29.6817
2010's56 (38.36)24.3611
2020's27 (18.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (3.18%)5.53%
Reviews9 (5.73%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other143 (91.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I Dose Escalation Study Using Pyrvinium Pamoate Targeting HuR in Pancreatic Ductal Adenocarcinoma [NCT05055323]Phase 118 participants (Anticipated)Interventional2021-07-29Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]